Highlights

• Inoviq Ltd shares are up 7.69% at AUD 0.21 during the 7 August 2026 session.

• INOVIQ released its June-quarter report in July after updates on the EXO-OC algorithm and clinical study.

• The company has a market capitalisation of approximately AUD 29.56mn in the current intraday snapshot.

• The stock is 47.50% lower over one year, placing today's move within a wider longer-term trend.

Inoviq Ltd (ASX:IIQ) is drawing fresh market attention during Friday trade, but the story behind the move is different from a simple one-day gain. The shares are up 7.69% at AUD 0.21 in the 7 August 2026 intraday snapshot, with turnover of AUD 28,157. Recent company activity is centred on EXO-OC ovarian cancer test. INOVIQ released its June-quarter report in July after updates on the EXO-OC algorithm and clinical study. The company also reported positive CAR-exosome data in ovarian cancer and held an investor briefing on the EXO-OC study outcome. With the market still open, the immediate price move remains fluid; the more important question is whether the latest operational or corporate steps translate into measurable progress.

Company Overview

INOVIQ is a biotechnology company developing exosome-based diagnostics and therapeutics, with programmes spanning ovarian cancer detection and exosome-related technologies.

Recent Developments

INOVIQ released its June-quarter report in July after updates on the EXO-OC algorithm and clinical study. The company also reported positive CAR-exosome data in ovarian cancer and held an investor briefing on the EXO-OC study outcome.

The update keeps EXO-OC ovarian cancer test at the centre of the near-term narrative. For Inoviq Ltd, the next phase is less about the headline announcement itself and more about execution: converting the latest milestone into operating, technical or commercial evidence that can be measured in subsequent reporting.

Financial Snapshot

In the current 7 August 2026 market snapshot, IIQ is trading at AUD 0.21, up 7.69%. Turnover is approximately AUD 28,157, while market capitalisation is about AUD 29.56mn. Over one year, the shares are 47.50% lower. Because the ASX session is still open, these figures are intraday and can change before the close.

Sector Context

Healthcare and biotechnology companies are driven by clinical evidence, regulatory progress and the ability to fund development through to commercialisation. Individual study or regulatory milestones can therefore materially affect market expectations.

What to Watch

Further validation of EXO-OC, regulatory planning, clinical development and funding requirements are the key areas to monitor.

Risks

Biotechnology programmes face clinical, regulatory, validation, commercialisation and funding risks.